scholarly journals Giant morphea-form basal cell carcinoma of the umbilicus: Successful debulking with vismodegib

Rare Tumors ◽  
2018 ◽  
Vol 10 ◽  
pp. 203636131877293 ◽  
Author(s):  
Mariana Orduz Robledo ◽  
Eve Lebas ◽  
Marie-Annick Reginster ◽  
Mahmoud Baghaie ◽  
Sabine Groves ◽  
...  
Keyword(s):  
Basal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Basal Cell ◽  
Treatment Plan ◽  
Sequential Treatment ◽  
Basal Cell Carcinomas ◽  
Cd56 Expression ◽  
Main Representative ◽  
Form Type ◽  
Giant Basal Cell Carcinoma

Basal cell carcinoma of the umbilicus is very rare. The nodular subtype is the main representative. Giant basal cell carcinomas represent around 1% of all basal cell carcinomas. The hedgehog pathway inhibitor vismodegib is indicated for advanced basal cell carcinoma and CD56-negative immunostaining seems indicative for successful treatment. A 54-year-old man presented a 10 cm × 14 cm large and 4.5 cm deep morphea-form basal cell carcinoma with faint immunohistochemical CD56 expression arising from the umbilicus. A sequential treatment was initiated with debulking using vismodegib 150 mg per day for 4 months, followed by reconstructive surgery. To the best of our knowledge, this is the first report of a giant basal cell carcinoma of the morphea-form type of the umbilicus. The sequential treatment plan reduces the duration of vismodegib inherent adverse effects and significantly reduces the tumor mass prior to surgery. Besides increasing adherence to vismodegib treatment, this approach facilitates the surgical technique and improves cosmetic outcome.

scholarly journals Giant Basal Cell Carcinoma – a Case Report

2018 ◽  
Vol 10 (3) ◽  
pp. 83-89
Author(s):  
Igor Kapetanović ◽  
Vesna Reljić ◽  
Martina Bosić ◽  
Svetlana Popadić
Keyword(s):  
Basal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Basal Cell ◽  
Slow Growth ◽  
Rare Type ◽  
Basal Cell Carcinomas ◽  
The Right ◽  
Electron Radiotherapy ◽  
Giant Basal Cell Carcinoma ◽  
Cutaneous Cancer

Abstract Basal cell carcinoma is the most common form of cutaneous cancer. In majority of cases it is locally invasive with slow growth, ranging in size from a couple of milimeters to a couple of centimeters and located primarily on sun-exposed regions. Giant basal cell carcinoma, defined as a tumor that is larger than 5 cm in diameter, is a very rare type of cutaneous malignancy accounting for 0.5-1% of all basal cell carcinomas. We present a case of a 74-year-old man with a 17 x 14 cm giant basal cell carcinoma in the right supraclavicular region. Detailed history revealed that the lesion had started as a papule 15 years before presentation. Despite its growth, the lesion was neglected until admission. Histological examination of skin lesion confirmed superficial and focally infiltrative types of basal cell carcinoma. Electron radiotherapy was administered with 54 Gy total dose delivered in 20 daily fractions which resulted in healing of lesions and adequate response. Thus, definitive radiotherapy can be just as effective as excision when the criteria are met.

Two Cases of Giant Basal Cell Carcinoma of the Vulva

2005 ◽  
Vol 67 (6) ◽  
pp. 584-589 ◽  
Author(s):  
Tadamasa YAMAMOTO ◽  
Sachiko TAKEICHI ◽  
Daisuke FUKUMOTO ◽  
Hirotsugu TAKIWAKI ◽  
Seiji ARASE ◽  
...  
Keyword(s):  
Basal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Basal Cell ◽  
Giant Basal Cell Carcinoma

Basal Cell Carcinoma of Prostate With MSMB–NCOA4 Fusion and a Probable Basal Cell Carcinoma In Situ: Case Report

2021 ◽  
pp. 106689692110173
Author(s):  
Vilde Pedersen ◽  
Katrine S. Petersen ◽  
Klaus Brasso ◽  
Olga Østrup ◽  
Anand C. Loya
Keyword(s):  
Prostate Cancer ◽  
Basal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Basal Cell ◽  
Carcinoma In Situ ◽  
Pathological Examination ◽  
Molecular Characteristics ◽  
Histological Lesion ◽  
Basal Cell Carcinomas

Basal cell carcinomas of prostate (BCCP) are very rare. Most arise in the transition zone and thus are associated with lower urinary tract symptoms and rarely associated with elevated prostate-specific antigen (PSA). These features make diagnosis/early diagnosis difficult because of the routine protocols followed. Basal cell carcinomas have distinctive histopathological, immunohistochemical, and to some extent also different molecular characteristics. Basal cell carcinoma in situ (BCCIS) is a nonexistent histological lesion as per the current literature, but here is an attempt to describe it through this case. A 74-year-old man presented with hematuria and previous diagnosis of prostatic hyperplasia. Based on this history, he underwent a prostatectomy ad modum Freyer. Pathological examination surprisingly revealed a diffusely infiltrative tumor with nonacinar adenocarcinoma morphology and many glandular structures probably representing BCCIS. Tumor was diagnosed as BCCP. Patient presented with metastasis to the abdominal wall 8 months postprostatectomy. BCCP is an aggressive type of prostate cancer, which might be challenging to diagnose based on routine protocols. This results in delayed diagnosis and treatment and thus poor prognosis. Furthermore, patients with this subtype of prostate cancer need appropriately designed, and maybe a totally different follow-up regimen as PSA is of no use for BCCP patients. Finally, diagnosis of BCCIS, if agreed upon its existence needs to be studied in larger cohorts as a precursor lesion.

scholarly journals Imiquimod 5% cream in the treatment of superficial and nodular basal cell carcinomas: study of 10 cases

2002 ◽  
Vol 77 (6) ◽  
pp. 693-698 ◽  
Author(s):  
Cyro Festa Neto
Keyword(s):  
Basal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Basal Cell ◽  
Topical Treatment ◽  
Imiquimod Cream ◽  
Basal Cell Carcinomas ◽  
Different Types

BACKGROUND: Topical treatment with 5% imiquimod cream has been demonstrated to be effective in patients with basal cell carcinoma. OBJECTIVES: In the present study, efficacy and tolerability of this treatment was analyzed in 10 patients with 13 different types of superficial and nodular basal cell carcinomas. METHODS: Imiquimod cream was applied daily for a mean period of 23 days. RESULTS AND CONCLUSIONS: All patients responded favorably to the drug with healing of the lesions. No recurrence was observed during two to three months of follow up.

Giant basal cell carcinoma: clinical–histological characteristics of 115 cases

2019 ◽  
Vol 58 (12) ◽  
pp. 1430-1434 ◽  
Author(s):  
Martha R. Vaca‐Aguilera ◽  
Elizabeth Guevara‐Gutiérrez ◽  
Juan G. Barrientos‐García ◽  
Alberto Tlacuilo‐Parra
Keyword(s):  
Basal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Basal Cell ◽  
Histological Characteristics ◽  
Giant Basal Cell Carcinoma

Giant basal cell carcinoma affecting the lower abdominal, genital and bilateral inguinal regions

2002 ◽  
Vol 55 (5) ◽  
pp. 445-448 ◽  
Author(s):  
Mamoru Kikuchi ◽  
Kenji Yano ◽  
Tateki Kubo ◽  
Ko Hosokawa ◽  
Yuji Yamaguchi ◽  
...  
Keyword(s):  
Basal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Basal Cell ◽  
Giant Basal Cell Carcinoma

Giant Basal Cell Carcinoma of the Forehead with Extensive Intracranial Involvement

2007 ◽  
Vol 116 (9) ◽  
pp. 663-666 ◽  
Author(s):  
Ilka Charlotte Naumann ◽  
Susan R. Cordes
Keyword(s):  
Skin Lesion ◽  
Basal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Basal Cell ◽  
Growth Pattern ◽  
Cancer Surveillance ◽  
Review Of The Literature ◽  
Intracranial Involvement ◽  
Malignant Skin ◽  
Giant Basal Cell Carcinoma

Basal cell carcinoma (BCC) is the most common malignant skin lesion and is frequently curatively treated with local excision. Improper removal or neglect of BCC is a particular problem for head and neck surgeons. We describe a case of a recurrent BCC that aggressively grew from the forehead skin through the skull and into the frontal lobe. We also present a review of the literature. Despite its fairly benign growth pattern, BCC should never be underestimated, and care should be taken not only in the complete primary excision but also in cancer surveillance.

Sign in / Sign up

Export Citation Format

Share Document